Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Cash & Equivalents: 2011-2024

Historic Cash & Equivalents for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to $104.4 million.

  • Mimedx Group's Cash & Equivalents rose 60.00% to $142.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.1 million, marking a year-over-year increase of 60.00%. This contributed to the annual value of $104.4 million for FY2024, which is 27.34% up from last year.
  • Latest data reveals that Mimedx Group reported Cash & Equivalents of $104.4 million as of FY2024, which was up 27.34% from $82.0 million recorded in FY2023.
  • In the past 5 years, Mimedx Group's Cash & Equivalents ranged from a high of $104.4 million in FY2024 and a low of $66.0 million during FY2022.
  • In the last 3 years, Mimedx Group's Cash & Equivalents had a median value of $82.0 million in 2023 and averaged $84.1 million.
  • In the last 5 years, Mimedx Group's Cash & Equivalents spiked by 38.72% in 2020 and then dropped by 24.27% in 2022.
  • Over the past 5 years, Mimedx Group's Cash & Equivalents (Yearly) stood at $95.8 million in 2020, then fell by 9.11% to $87.1 million in 2021, then dropped by 24.27% to $66.0 million in 2022, then grew by 24.34% to $82.0 million in 2023, then increased by 27.34% to $104.4 million in 2024.